TY  - JOUR
A1  - Scholze, Alexandra
A1  - Liu, Ying
A1  - Pedersen, Lise
A1  - Xia, Shengqiang
A1  - Roth, Heinz J.
A1  - Hocher, Berthold
A1  - Rasmussen, Lars Melholt
A1  - Tepel, Martin
T1  - Soluble alpha-Klotho and its relation to kidney function and fibroblast growth factor-23
JF  - The journal of clinical endocrinology & metabolism
N2  - Context: Relations between fibroblast growth factor-23 (FGF-23), soluble alpha-klotho (s-alpha-klotho), and kidney function in chronic kidney disease (CKD) are still unclear. Especially the role of s-alpha-klotho requires further study.
 Objectives: Our objectives were to analyze the relation of s-alpha-klotho to estimated glomerular filtration rate (eGFR), FGF-23, and other parameters of calcium-phosphate metabolism and to investigate the response of s-alpha-klotho to cholecalciferol.
 Patients, Design, and Setting: Twenty-four CKD (stage 1-5) patients participated in this 8-week randomized controlled trial (vitamin D and chronic renal insufficiency).
 Interventions: Interventions included 40 000 IU cholecalciferol or placebo weekly.
 Main Outcome Measure: S-alpha-klotho was determined by ELISA with antihuman klotho antibodies 67G3 and 91F1.
 Results: For all patients, s-alpha-klotho concentrations did not differ between CKD stages. When patients were subdivided based on FGF-23 concentrations, a positive association of s-alpha-klotho with eGFR became apparent in patients with lower than median FGF-23 concentrations but not in those above median value. Patients with s-alpha-klotho below 204 pg/mL showed higher age, lower phosphate clearance, and lower bone-specific alkaline phosphatase compared with patients with higher s-alpha-klotho. Treatment with cholecalciferol significantly increased 1,25-dihydroxyvitamin D. The increase of FGF-23 had only borderline significance. There was no significant effect of high-dose cholecalciferol administration for 8 weeks on plasma s-alpha-klotho.
 Conclusions: CKD patients with s-alpha-klotho below 204 pg/mL had higher age, lower phosphate clearance, and lower bone-specific alkaline phosphatase. An association of s-alpha-klotho with eGFR was observed only in the presence of close to normal, but not high, FGF-23 concentrations. Cholecalciferol treatment did not change s-alpha-klotho concentrations.
Y1  - 2014
U6  - https://doi.org/10.1210/jc.2013-4171
SN  - 0021-972X
SN  - 1945-7197
VL  - 99
IS  - 5
SP  - E855
EP  - E861
PB  - Endocrine Society
CY  - Washington
ER  -